Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Precision medicine applications in prostate cancer.

McCrea EM, Lee DK, Sissung TM, Figg WD.

Ther Adv Med Oncol. 2018 Jun 18;10:1758835918776920. doi: 10.1177/1758835918776920. eCollection 2018. Review.

2.

A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.

Peer CJ, Hall OM, Sissung TM, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.

Cancer Chemother Pharmacol. 2018 Jun 27. doi: 10.1007/s00280-018-3631-7. [Epub ahead of print]

PMID:
29951694
3.

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.

Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.

4.

Pharmacogenomics Implementation at the National Institutes of Health Clinical Center.

Sissung TM, McKeeby JW, Patel J, Lertora JJ, Kumar P, Flegel WA, Adams SD, Eckes EJ, Mickey F, Plona TM, Mellot SD, Baugher RN, Wu X, Soppet DR, Barcus ME, Datta V, Pike KM, DiPatrizio G, Figg WD, Goldspiel BR.

J Clin Pharmacol. 2017 Oct;57 Suppl 10:S67-S77. doi: 10.1002/jcph.993. Review.

PMID:
28921647
5.

A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.

Grohar PJ, Glod J, Peer CJ, Sissung TM, Arnaldez FI, Long L, Figg WD, Whitcomb P, Helman LJ, Widemann BC.

Cancer Chemother Pharmacol. 2017 Sep;80(3):645-652. doi: 10.1007/s00280-017-3382-x. Epub 2017 Jul 22.

PMID:
28735378
6.

Discussing the predictive, prognostic, and therapeutic value of germline DNA-repair gene mutations in metastatic prostate cancer patients.

Hauke RJ Jr, Sissung TM, Figg WD.

Cancer Biol Ther. 2017 Aug 3;18(8):545-546. doi: 10.1080/15384047.2017.1345398. Epub 2017 Jul 5.

7.

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms.

Sissung TM, Peer CJ, Korde N, Mailankody S, Kazandjian D, Venzon DJ, Landgren O, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):217-221. doi: 10.1007/s00280-017-3323-8. Epub 2017 May 9.

PMID:
28488026
8.

Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.

Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie S, Peer CJ, Shukla S, van Velkinburgh J, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, Venzon DJ, Brenner S, Lee W, Merino M, Luo J, Jager W, Price DK, Chau CH, Figg WD.

Mol Cancer Res. 2017 Aug;15(8):1096-1105. doi: 10.1158/1541-7786.MCR-16-0477. Epub 2017 Apr 7.

PMID:
28389619
9.

Identification of novel SNPs associated with risk and prognosis in patients with castration-resistant prostate cancer.

Sissung TM, Deeken J, Leibrand CR, Price DK, Ehrlich S, Steinberg SM, Liewehr DJ, Dahut W, Figg WD.

Pharmacogenomics. 2016 Dec;17(18):1979-1986. Epub 2016 Nov 24.

10.

Androgen receptor variation affects prostate cancer progression and drug resistance.

McCrea E, Sissung TM, Price DK, Chau CH, Figg WD.

Pharmacol Res. 2016 Dec;114:152-162. doi: 10.1016/j.phrs.2016.10.001. Epub 2016 Oct 7. Review.

11.

Pharmacogenomics and histone deacetylase inhibitors.

Goey AK, Sissung TM, Peer CJ, Figg WD.

Pharmacogenomics. 2016 Nov;17(16):1807-1815. Epub 2016 Oct 21. Review.

12.

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.

Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC.

Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.

13.

Alcohol and Aldehyde Dehydrogenases Contribute to Sex-Related Differences in Clearance of Zolpidem in Rats.

Peer CJ, Strope JD, Beedie S, Ley AM, Holly A, Calis K, Farkas R, Parepally J, Men A, Fadiran EO, Scott P, Jenkins M, Theodore WH, Sissung TM.

Front Pharmacol. 2016 Aug 15;7:260. doi: 10.3389/fphar.2016.00260. eCollection 2016.

14.

Erratum to: Association of a CYP17 Polymorphism With Overall Survival in Caucasian Patients With Androgen-independent Prostate Cancer.

Sissung TM, Venzon DJ, Figg WD.

Urology. 2016 Sep;95:225. doi: 10.1016/j.urology.2016.05.047. Epub 2016 Jul 14. No abstract available.

15.

Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction.

Goey AK, Chau CH, Sissung TM, Cook KM, Venzon DJ, Castro A, Ransom TR, Henrich CJ, McKee TC, McMahon JB, Grkovic T, Cadelis MM, Copp BR, Gustafson KR, Figg WD.

J Nat Prod. 2016 May 27;79(5):1267-75. doi: 10.1021/acs.jnatprod.5b00846. Epub 2016 May 3.

PMID:
27140429
16.

Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease.

Nicoli ER, Al Eisa N, Cluzeau CV, Wassif CA, Gray J, Burkert KR, Smith DA, Morris L, Cologna SM, Peer CJ, Sissung TM, Uscatu CD, Figg WD, Pavan WJ, Vite CH, Porter FD, Platt FM.

PLoS One. 2016 Mar 28;11(3):e0152007. doi: 10.1371/journal.pone.0152007. eCollection 2016.

17.

UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.

Peer CJ, Goey AK, Sissung TM, Erlich S, Lee MJ, Tomita Y, Trepel JB, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.

J Clin Pharmacol. 2016 Apr;56(4):450-60. doi: 10.1002/jcph.627. Epub 2015 Dec 4.

PMID:
26637161
18.

Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis.

Fatima N, Cohen DC, Sukumar G, Sissung TM, Schooley JF Jr, Haigney MC, Claycomb WC, Cox RT, Dalgard CL, Bates SE, Flagg TP.

Front Pharmacol. 2015 Aug 13;6:168. doi: 10.3389/fphar.2015.00168. eCollection 2015.

19.

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.

Goey AK, Sissung TM, Peer CJ, Trepel JB, Lee MJ, Tomita Y, Ehrlich S, Bryla C, Balasubramaniam S, Piekarz R, Steinberg SM, Bates SE, Figg WD.

J Clin Pharmacol. 2016 Apr;56(4):461-73. doi: 10.1002/jcph.625. Epub 2015 Nov 9.

PMID:
26313268
20.

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Wu P, Morrison C, Costello R, Zhang Y, Burton D, Mulquin M, Zuchlinski D, Lamping L, Carpenter A, Wall Y, Carter G, Cunningham SC, Gounden V, Sissung TM, Peer C, Maric I, Calvo KR, Braylan R, Yuan C, Stetler-Stevenson M, Arthur DC, Kong KA, Weng L, Faham M, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Figg W, Landgren O.

JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.

PMID:
26181891
21.

Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells.

Fernandez EV, Reece KM, Ley AM, Troutman SM, Sissung TM, Price DK, Chau CH, Figg WD.

Mol Pharmacol. 2015 Jun;87(6):1006-12. doi: 10.1124/mol.114.097477. Epub 2015 Mar 31.

22.

Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.

Akshintala S, Marcus L, Warren KE, Murphy RF, Sissung TM, Srivastava A, Goodspeed WJ, Goodwin A, Brewer CC, Zalewski C, King KA, Kim A, Figg WD, Widemann BC.

Pediatr Blood Cancer. 2015 Apr;62(4):603-10. doi: 10.1002/pbc.25344. Epub 2015 Jan 3.

23.

Genetic variation: effect on prostate cancer.

Sissung TM, Price DK, Del Re M, Ley AM, Giovannetti E, Figg WD, Danesi R.

Biochim Biophys Acta. 2014 Dec;1846(2):446-56. doi: 10.1016/j.bbcan.2014.08.007. Epub 2014 Sep 6. Review.

24.

Pharmacogenetics of membrane transporters: a review of current approaches.

Sissung TM, Goey AK, Ley AM, Strope JD, Figg WD.

Methods Mol Biol. 2014;1175:91-120. doi: 10.1007/978-1-4939-0956-8_6. Review.

PMID:
25150868
25.

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.

J Natl Cancer Inst. 2014 May 19;106(6):dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.

26.

Multi-institutional Study of Outcomes After Pediatric Heart Transplantation: Candidate Gene Polymorphism Analysis of ABCC2.

Burckart GJ, Figg WD 2nd, Brooks MM, Green DJ, Troutman SM, Ferrell R, Chinnock R, Canter C, Addonizio L, Bernstein D, Kirklin JK, Naftel D, Price DK, Sissung TM, Girnita DM, Zeevi A, Webber SA.

J Pediatr Pharmacol Ther. 2014 Jan;19(1):16-24. doi: 10.5863/1551-6776-19.1.16.

27.

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.

Clin Genitourin Cancer. 2013 Sep;11(3):229-37. doi: 10.1016/j.clgc.2013.04.007. Epub 2013 May 17.

28.

Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.

Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon DJ, Flagg TP, Haigney MC, Steinberg SM, Figg WD, Piekarz RL, Bates SE.

Clin Cancer Res. 2013 Jun 1;19(11):3095-104. doi: 10.1158/1078-0432.CCR-13-0109. Epub 2013 Apr 15.

29.

Contribution of the OATP1B subfamily to cancer biology and treatment.

Sissung TM, Reece KM, Spencer S, Figg WD.

Clin Pharmacol Ther. 2012 Nov;92(5):658-60. doi: 10.1038/clpt.2012.127. Epub 2012 Sep 26. Review. No abstract available.

PMID:
23010650
30.

Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer.

Pratt E, Sissung TM, Figg WD.

Cancer Biol Ther. 2012 Dec;13(14):1374-5. doi: 10.4161/cbt.22010. Epub 2012 Sep 6.

31.

Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.

Troutman SM, Sissung TM, Cropp CD, Venzon DJ, Spencer SD, Adesunloye BA, Huang X, Karzai FH, Price DK, Figg WD.

Oncologist. 2012;17(3):312-20. doi: 10.1634/theoncologist.2011-0315. Epub 2012 Mar 1.

32.

Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.

Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD.

Clin Cancer Res. 2012 Apr 1;18(7):2099-107. doi: 10.1158/1078-0432.CCR-11-2484. Epub 2012 Feb 3.

33.

Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Sissung TM, Troutman SM, Campbell TJ, Pressler HM, Sung H, Bates SE, Figg WD.

Discov Med. 2012 Jan;13(68):19-34. Review.

34.

SLCO transport genes in prostate cancer--letter.

Sissung TM, Pressler H, Price DK, Figg WD.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2325; author reply 2326-7. doi: 10.1158/1055-9965.EPI-11-0606. Epub 2011 Sep 6. No abstract available.

35.

Expression of OATP family members in hormone-related cancers: potential markers of progression.

Pressler H, Sissung TM, Venzon D, Price DK, Figg WD.

PLoS One. 2011;6(5):e20372. doi: 10.1371/journal.pone.0020372. Epub 2011 May 19.

36.

CHIP and gp78-mediated ubiquitination of CYP3A4: Implications for the pharmacology of anticancer agents.

Peer CJ, Sissung TM, Figg WD.

Cancer Biol Ther. 2011 Mar 15;11(6):549-51. Epub 2011 Mar 15. Review.

37.

A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer.

English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, Price DK, Figg WD.

Ther Clin Risk Manag. 2010 Nov 19;6:579-83. doi: 10.2147/TCRM.S14303.

38.

Impact of ABCB1 allelic variants on QTc interval prolongation.

Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD.

Clin Cancer Res. 2011 Feb 15;17(4):937-46. doi: 10.1158/1078-0432.CCR-10-0925. Epub 2010 Nov 24.

39.

Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.

Sissung TM, Danesi R, Kirkland CT, Baum CE, Ockers SB, Stein EV, Venzon D, Price DK, Figg WD.

J Clin Endocrinol Metab. 2011 Feb;96(2):E368-72. doi: 10.1210/jc.2010-2070. Epub 2010 Nov 24.

40.

Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.

Smith NF, Mani S, Schuetz EG, Yasuda K, Sissung TM, Bates SE, Figg WD, Sparreboom A.

Ann Pharmacother. 2010 Nov;44(11):1709-17. doi: 10.1345/aph.1P354. Epub 2010 Oct 19.

41.

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.

Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R.

BMC Cancer. 2010 Sep 27;10:511. doi: 10.1186/1471-2407-10-511.

42.

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.

Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, Venzon D, Liewehr D, English BC, Baum CE, Yarchoan R, Giaccone G, Venitz J, Price DK, Figg WD.

J Exp Clin Cancer Res. 2010 Jul 14;29:95. doi: 10.1186/1756-9966-29-95.

43.

Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism.

Sharma H, Sissung TM, Pressler H, Figg WD.

Cancer Biol Ther. 2010 Feb;9(3):163-5. Epub 2010 Feb 6.

PMID:
20087060
44.

More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer.

Ajiboye S, Sissung TM, Sharifi N, Figg WD.

BJU Int. 2010 Apr;105(7):913-6. doi: 10.1111/j.1464-410X.2009.08999.x. Epub 2010 Jan 8. Review.

45.

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.

Deeken JF, Cormier T, Price DK, Sissung TM, Steinberg SM, Tran K, Liewehr DJ, Dahut WL, Miao X, Figg WD.

Pharmacogenomics J. 2010 Jun;10(3):191-9. doi: 10.1038/tpj.2009.57. Epub 2009 Dec 29.

PMID:
20038957
46.

Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform.

Sissung TM, English BC, Venzon D, Figg WD, Deeken JF.

Pharmacogenomics. 2010 Jan;11(1):89-103. doi: 10.2217/pgs.09.154. Review.

PMID:
20017675
47.

Pharmacogenetics of membrane transporters: an update on current approaches.

Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD.

Mol Biotechnol. 2010 Feb;44(2):152-67. doi: 10.1007/s12033-009-9220-6. Review.

PMID:
19950006
48.

A genomic strategy for predicting androgen receptor activity in prostate tumors.

Jonsson JG, Sissung TM, Figg WD.

Cancer Biol Ther. 2009 Nov;8(21):2002-3. Epub 2009 Nov 25.

PMID:
19838047
49.

The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors.

Jain L, Vargo CA, Danesi R, Sissung TM, Price DK, Venzon D, Venitz J, Figg WD.

Mol Cancer Ther. 2009 Sep;8(9):2496-508. doi: 10.1158/1535-7163.MCT-09-0302. Epub 2009 Sep 15. Review.

50.

Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Sissung TM, Thordardottir S, Gardner ER, Figg WD.

Anticancer Agents Med Chem. 2009 Dec;9(10):1058-69. Review.

PMID:
19719457

Supplemental Content

Loading ...
Support Center